JAK/TYK2

JAK Inhibitors Reduce Macular Degeneration Insurance claims data showed that patients with autoimmune disorders who took JAK inhibitors had lower rates of AMD, hinting that the drugs might treat the common eye disease. https://t.co/bx0UCp0o3r https://t.co/FXSlcFHYXI

Links:

Dr. John Cush @RheumNow( View Tweet )
eye.exam_.equip_.jpg

JAK Inhibitors Reduce Macular Degeneration

Mepage Today

Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.

Read Article
AbbVie has submitted regulatory applications to both the FDA and the European Medicines Agency for Rinvoq (upadacitinib) to treat adult patients with giant cell arteritis (GCA) https://t.co/LqRcm2FEFV https://t.co/XEjjSNnOGt

Links:

Dr. John Cush @RheumNow( View Tweet )
FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://t.co/IVsGwqpiJK https://t.co/4epOHdNHbO

Links:

Dr. John Cush @RheumNow( View Tweet )
FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://t.co/BmNPk6zN6o https://t.co/fbzHQmPmH5

Links:

Dr. John Cush @RheumNow( View Tweet )
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024

Dr. John Cush @RheumNow( View Tweet )

New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/yyayyPcN9L https://t.co/4IQfmvbg4G

Links:

Dr. John Cush @RheumNow( View Tweet )
JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/eF6wO72D80 https://t.co/IFDYuI71X5

Links:

Dr. John Cush @RheumNow( View Tweet )
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020

Dr. John Cush @RheumNow( View Tweet )

Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy

Links:

Dr. John Cush @RheumNow( View Tweet )
JAK Inhibitors in GCA Trials are underway evaluating the potential benefits of JAKi in GCA patients who are refractory to standards of care. An observational real-world analysis of a small worldwide cohort suggests the utility of JAKi in GCA. https://t.co/d4IsqBgkxQ https://t.co/PIDhwzgNym

Links:

Dr. John Cush @RheumNow( View Tweet )
RT @yuz6yusof #EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) #EULARBEST

Dr. John Cush @RheumNow( View Tweet )

RheumNow Podcast square

Future Big BiTEs (6.28.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13

Links:

Dr. John Cush @RheumNow( View Tweet )
GCA,woman

JAK Inhibitors in Giant Cell Arteritis

Jack Cush, MD

Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care. An observational real-

Read Article
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT: data now out to 60w good humoral and cellular response in most, even without MTX withheld (& good safety too) Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020

Dr. John Cush @RheumNow( View Tweet )

Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG

Links:

Dr. John Cush @RheumNow( View Tweet )
JAK Janus

New indications for JAK inhibitors

Janet Pope, MD, MPH, FRCPC

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. https://t.co/vN2VZYGqbE https://t.co/MQ3QCJU4SW

Links:

Dr. John Cush @RheumNow( View Tweet )
EULAR24,Roundup

EULAR 2024 Rheumatology Roundup (6.21.2024)

Jack Cush, MD

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. https://t.co/G96x5UMZOX https://t.co/4cOuIbcHVt

Links:

Dr. John Cush @RheumNow( View Tweet )
Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. https://t.co/HKapiAIHSs https://t.co/QrO4pVNOTo

Links:

Dr. John Cush @RheumNow( View Tweet )
Impact of regulatory warning on JAK inhibitors JAK inhibitors show promise for treating inflammatory rheumatic diseases, but ORAL surveillance 2022 found increased risk of MACE, cancer, and death. https://t.co/BEYgUg1DF4 https://t.co/tsjOZ6emDg

Links:

Dr. John Cush @RheumNow( View Tweet )
RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i? IL17i? JAKi? @eular_org # LBA0001 @Janetbirdope https://t.co/DGOltriVYF
Dr. John Cush @RheumNow( View Tweet )
Convention1.jpg

EULAR 2024 – Day 4 Report

Jack Cush, MD

The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations.  Below is a synopsis of the half-day's action.

Read Article

Recent Blogs

JAKi for PMR: Safe, or a Concern for Older Adults?

David Liew, FRACP
Dr. David Liew
JAK inhibitors obviously have dominated a lot of the discussion in our therapeutic landscape over the last couple of years. What about their use in polymyalgia rheumatica? Let's consider. Read Post

Infections Rheums Should Worry About

Cassandra Calabrese, DO
TB.EMimage.CDC_.jpg
With the increasing development and use of new biologics and oral targeted therapies to treat RA and other immune mediated inflammatory diseases, an awareness of infection risk and prevention has become of increasing interest as well. While our patients may be susceptible to many different types of infections depending on immunosuppressive regimen, age and co-morbidities, I’ll highlight a few of the “usual suspects”. Read Post

Featured Video

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.